| 2025-12-12 |
详情>>
内部人交易：
Apuli Maricel等共交易6笔
|
| 2025-10-29 |
详情>>
股本变动：
变动后总股本19270.88万股
|
| 2025-10-29 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-2.79美元,归母净利润-5.32亿美元,同比去年增长-96.54%
|
| 2025-10-29 |
财报披露：
美东时间 2025-10-29 盘后发布财报
|
| 2025-08-05 |
详情>>
业绩披露：
2025年中报每股收益-1.84美元,归母净利润-3.49亿美元,同比去年增长-221.45%
|
| 2025-04-30 |
股东大会：
将于2025-06-20召开股东大会
会议内容 ▼▲
- 1.To elect five (5) nominees for director, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels, and Andrew W. Lo, Ph.D. to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2027, and until their successors are duly elected and qualified.
2.To approve, on an advisory basis, the compensation of our named executive officers (NEOs), as disclosed in the Proxy Statement.
3.To ratify the selection of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.
4.To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by 5,000,000 shares.
5.To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to include an officer exculpation provision that limits the liability of certain of our officers as permitted under current Delaware law.
6.To approve the adjournment of the Annual Meeting to the extent there are insufficient votes at the Annual Meeting to approve any of the above proposals.
7.To transact such other business as may properly be brought before the Annual Meeting.
|
| 2025-04-29 |
详情>>
业绩披露：
2025年一季报每股收益-0.88美元,归母净利润-1.67亿美元,同比去年增长-375.41%
|
| 2025-02-20 |
详情>>
业绩披露：
2022年年报每股收益-3.26美元,归母净利润-4.81亿美元,同比去年增长14.46%
|
| 2025-02-20 |
详情>>
业绩披露：
2024年年报每股收益-2.88美元,归母净利润-5.36亿美元,同比去年增长16.70%
|
| 2024-11-23 |
复牌提示：
2024-11-22 16:08:53 停牌，复牌日期 2024-11-25 07:10:00
|
| 2024-11-12 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-1.46美元,归母净利润-2.71亿美元,同比去年增长43.01%
|
| 2024-08-01 |
详情>>
业绩披露：
2024年中报每股收益-0.59美元,归母净利润-1.09亿美元,同比去年增长63.54%
|
| 2024-08-01 |
详情>>
业绩披露：
2023年中报每股收益-1.9美元,归母净利润-2.98亿美元,同比去年增长-44.51%
|
| 2024-05-02 |
详情>>
业绩披露：
2024年一季报每股收益-0.2美元,归母净利润-3521.6万美元,同比去年增长74.87%
|
| 2024-04-25 |
股东大会：
将于2024-06-21召开股东大会
会议内容 ▼▲
- 1.To elect five (5) directors, Eric Aguiar, M.D., Jennifer E. Cook, Andrea J. Ellis, Fred Hassan and Ali J. Satvat, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2026 and until their successors are duly elected and qualified, or until such director’s earlier death, resignation or removal.
2.To cast a non-binding, advisory vote to approve the compensation of our named executive officers.
3.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2024.
4.To approve an amendment and restatement of the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 6,500,000 shares.
5.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2024-02-22 |
详情>>
业绩披露：
2023年年报每股收益-3.95美元,归母净利润-6.43亿美元,同比去年增长-33.67%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-2.99美元,归母净利润-4.75亿美元,同比去年增长-38.26%
|
| 2023-04-28 |
股东大会：
将于2023-06-21召开股东大会
会议内容 ▼▲
- 1.To elect four (4) directors, James C. Momtazee, Frank McCormick, Ph.D., Randal W. Scott, Ph.D. and Hannah A. Valantine, M.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2025 and until their successors are duly elected and qualified, or until such director’s earlier death, resignation or removal.
2.To cast a non-binding, advisory vote to approve the compensation of our named executive officers.
3.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2023.
4.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2022-04-29 |
股东大会：
将于2022-06-22召开股东大会
会议内容 ▼▲
- 1.To elect five (5) directors, Neil Kumar, Ph.D., Charles Homcy, M.D., Douglas A. Dachille, Ronald J. Daniels and Andrew W. Lo, Ph.D., to serve as Class III directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2024 and until their successors are duly elected and qualified, or until such director’s earlier death, resignation or removal.
2.To cast a non-binding, advisory vote to approve the compensation of our named executive officers.
3.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2022.
4.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2021-11-08 |
股东大会：
将于2021-12-15召开股东大会
会议内容 ▼▲
- 1.To consider and vote on a proposal to approve a resolution ratifying the equity awards granted to the Company’s directors in 2019, 2020 and 2021 under the Company’s Director Compensation Policy (“Proposal 1”);
2.To consider and vote on a proposal to approve the Company’s Amended and Restated Director Compensation Policy (“Proposal 2”). Approval of Proposal 1 by our stockholders is a condition to the adoption by the Company of the Amended and Restated Director Compensation Policy set forth in Proposal 2. Subject to and effective on the approval of Proposal 1 and Proposal 2, the Board of Directors has adopted amendments to the 2019 Incentive Plan, as described under “Proposal 2—2019 Incentive Plan Amendment” on page 22 of this proxy statement, to immediately eliminate re-pricing of stock option and stock appreciation rights without shareholder approval and to terminate the “evergreen” features of the 2019 Incentive Plan effective as of the Company’s 2023 annual meeting. If our stockholders do not approve Proposal 1 at the Special Meeting, Proposal 2 will be of no effect, regardless of the vote obtained on Proposal 2, and the 2019 Director Compensation Policy will continue in force in its current form, as will the 2019 Incentive Plan;
3.To consider and vote on a proposal to adjourn the Special Meeting, if necessary or appropriate to solicit additional votes in favor of Proposal 1 or Proposal 2 or to ensure that a quorum is present (“Proposal 3”, and together with Proposal 1 and Proposal 2, the “Proposals”).
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-30 |
股东大会：
将于2021-06-17召开股东大会
会议内容 ▼▲
- 1.To elect three (3) directors, Eric Aguiar, M.D., Ali Satvat and Jennifer E. Cook, to serve as Class II directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2023 and until their successors are duly elected and qualified, or until such director’s earlier death, resignation or removal.
2.To cast a non-binding, advisory vote to approve the compensation of our named executive officers.
3.To cast a non-binding, advisory vote on the frequency of future non-binding, advisory votes to approve the compensation of our named executive officers.
4.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2021.
5.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|
| 2020-12-15 |
股东大会：
将于2021-01-19召开股东大会
会议内容 ▼▲
- 1.To consider and vote on a proposal to approve the issuance of shares of BridgeBio common stock pursuant to the Agreement and Plan of Merger, dated as of October 5, 2020 (the “merger agreement”), by and among Eidos Therapeutics, Inc., BridgeBio, Globe Merger Sub I, Inc. and Globe Merger Sub II, Inc., a copy of which is attached as Annex A to the accompanying joint proxy statement/prospectus (the “BridgeBio share issuance proposal”);
2.To consider and vote on a proposal to adjourn the BridgeBio special meeting, if necessary or appropriate, to solicit additional proxies in the event there are not sufficient votes at the time of the BridgeBio special meeting to approve the BridgeBio share issuance proposal or to ensure that a quorum is present at the BridgeBio special meeting (the “BridgeBio adjournment proposal”).
|
| 2020-04-22 |
股东大会：
将于2020-06-02召开股东大会
会议内容 ▼▲
- 1.To elect two (2) directors, James C. Momtazee and Richard H. Scheller, Ph.D., to serve as Class I directors to hold office until the date of the annual meeting of stockholders following the year ending December 31, 2022 and until their successors are duly elected and qualified, or until such director’s earlier death, resignation or removal.
2.To ratify the appointment of Deloitte & Touche LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2020.
3.To approve an amendment and restatement of the Company’s 2019 Stock Option and Incentive Plan (the “Amended and Restated Plan”) to, among other things, increase the number of shares of common stock reserved for issuance thereunder by 2,500,000 shares.
4.To transact such other business as may properly come before the meeting or any adjournment or postponement thereof.
|